New guideline on treating COVID-19

29-Apr-2020 1:35 PM EDT, by McMaster University

 

Podcast: https://soundcloud.com/cmajpodcasts/200648-guide

Newswise — OTTAWA – An international team of physicians, pharmacists, medical researchers and patient partners has developed a clinical guideline for the treatment of patients with coronavirus disease 2019 (COVID-19), published in CMAJ (Canadian Medical Association Journal)VIEW ARTICLE

"The enormity of the adverse health consequences of COVID-19 has understandably left clinicians and patients eager for interventions that can decrease progression, prevent mortality and speed recovery," writes Dr. Gordon Guyatt, McMaster University, Hamilton, Ontario, and his coauthors. "This eagerness has perhaps contributed to overly sanguine assessments from experts, regulatory authorities and prominent politicians regarding the potential benefits of treatments, with underappreciation of potential harms."

The guideline, aimed at physicians and their patients, is based on the most recent available evidence as of April 25, 2020. It looks at treatments for patients with nonsevere and severe COVID-19. This comprehensive look at the quality of evidence found only low or very low-quality evidence supporting treatment benefit.

"As a result, the guideline panel made almost exclusively weak (conditional) recommendations against use of these agents in COVID-19 patients," says Dr. Guyatt.

Recommendations:

  • Weak recommendation in favour of using corticosteroids in patients with severe COVID-19 and acute respiratory distress syndrome (ARDS)
  • Weak recommendation against using corticosteroids in patients with COVID-19 but without ARDS
  • Weak recommendation against using convalescent plasma in patients with severe COVID-19
  • Weak recommendation against using several antiviral drugs currently under consideration for treatment in patients with severe and nonsevere COVID-19.

The authors caution that two very low-quality studies have raised the possibility that hydroxychloroquine could increase the risk of mechanical ventilation and death.

"The recommendations in this guideline should discourage use of interventions for which there is very low-quality evidence, thus decreasing medical waste. However, misleading statements about and advocacy for use of medications for which we were unable to find robust evidence of benefit at this time present the major barriers to this guideline's implementation," conclude the authors.

An international team of physicians, pharmacists and researchers from Canada, China, South Korea, Mexico, Saudi Arabia and Singapore, as well as two patient partners, created the guideline.

It will be available in various user-friendly formats for clinicians as well as patients on the MAGICApp and at cmaj.ca http://www.cmaj.ca/lookup/doi/10.1503/cmaj.200648

"Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline" is published April 29, 2020.

Please credit CMAJ, not the Canadian Medical Association (CMA). CMAJ is an independent medical journal; views expressed do not necessarily reflect those of its owner, Joule Inc., a CMA company, or CMA.

 

SEE ORIGINAL STUDY




Filters close

Showing results

1120 of 4578
Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San Antonio

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.

Released: 15-Jan-2021 11:20 AM EST
Will Covid-19 kill the high street once and for all?
University of Sheffield

The shift to home working during Covid-19, or ‘Zoomshock’, threatens the survival of local goods and services provided in city centres and business parks

14-Jan-2021 5:00 PM EST
AACI Partners With Federal Vaccine Panel to Promote Cancer Patient Health
Association of American Cancer Institutes (AACI)

AACI was invited last summer to join the Vaccine Consultation Panel (VCP) alongside other leading health and science organizations in the U.S. Through the VCP, AACI has received periodic updates on the development and distribution of COVID-19 vaccines and participated in efforts to educate the cancer center community and the general public on the importance of widespread vaccine uptake.

Released: 15-Jan-2021 8:55 AM EST
The First Dose of the Pfizer Vaccine Gives About 50% COVID Protection, Not 91% Claimed by Those Who Want to Speed Up Immunization
Newswise

The NEJM paper actually states that the efficacy between the first and second doses was found to be 52 percent when given 21 days apart. After the second dose, the efficacy raises to 95 percent.

Released: 15-Jan-2021 8:20 AM EST
Houston Methodist study finds males of all ages more affected by COVID-19 than females
Houston Methodist

A new Houston Methodist study found males are more likely to test positive for COVID-19, have complications and die from the virus than females, independent of age. The peer-reviewed observational study appears in PLOS ONE, a multidisciplinary journal published by the Public Library of Science.

Released: 15-Jan-2021 8:20 AM EST
NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19 Ivermectin is Now a Therapeutic Option for Doctors & Prescribers


Showing results

1120 of 4578

close
1.08079